Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence

Research output: Contribution to journalArticle

Abstract

The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence. Although several studies demonstrated that extended adjuvant endocrine therapy reduces the incidence of late recurrence, it remains unclear which hormone-receptor-positive patients have greater risks of late recurrence. Hormone-receptor-positive breast cancer patients were retrospectively selected from the prospective database of primary breast cancer patients treated at Keio University Hospital from January 1989 to December 2003. Late recurrence was defined as initial recurrence after 5 years from the initial surgery. We evaluated the clinicopathologic features of breast cancer patients with late recurrence. At a median follow-up of 10.9 years (range, 5.1-23.8), 371 patients had no recurrence, 90 had early recurrence (within 5 years), and 83 had late recurrence. Multivariate analysis revealed that >4 involved lymph nodes were significant risk factors for late recurrence (P < .001), whereas 1-3 positive nodes were not. Endocrine therapy significantly reduced the incidence of late recurrence (P < .001). After menopause, adjuvant therapy with aromatase inhibitors resulted in longer disease-free survival than tamoxifen (10-year disease-free survival: 97.6% vs 89.7%, P = .0955). High nodal involvement was significantly correlated with late recurrence in hormone-receptor-positive breast cancer patients. Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.

Original languageEnglish
JournalBreast Journal
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Hormones
Breast Neoplasms
Recurrence
Tamoxifen
Disease-Free Survival
Therapeutics
Aromatase Inhibitors
Incidence
Menopause
Survivors
Multivariate Analysis
Lymph Nodes
Databases

Keywords

  • Extended endocrine therapy
  • Hormone-receptor-positive breast cancer
  • Late recurrence

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Cite this

@article{a7706f5a2f3b4b0abe05fe396e0657e1,
title = "Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence",
abstract = "The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence. Although several studies demonstrated that extended adjuvant endocrine therapy reduces the incidence of late recurrence, it remains unclear which hormone-receptor-positive patients have greater risks of late recurrence. Hormone-receptor-positive breast cancer patients were retrospectively selected from the prospective database of primary breast cancer patients treated at Keio University Hospital from January 1989 to December 2003. Late recurrence was defined as initial recurrence after 5 years from the initial surgery. We evaluated the clinicopathologic features of breast cancer patients with late recurrence. At a median follow-up of 10.9 years (range, 5.1-23.8), 371 patients had no recurrence, 90 had early recurrence (within 5 years), and 83 had late recurrence. Multivariate analysis revealed that >4 involved lymph nodes were significant risk factors for late recurrence (P < .001), whereas 1-3 positive nodes were not. Endocrine therapy significantly reduced the incidence of late recurrence (P < .001). After menopause, adjuvant therapy with aromatase inhibitors resulted in longer disease-free survival than tamoxifen (10-year disease-free survival: 97.6{\%} vs 89.7{\%}, P = .0955). High nodal involvement was significantly correlated with late recurrence in hormone-receptor-positive breast cancer patients. Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.",
keywords = "Extended endocrine therapy, Hormone-receptor-positive breast cancer, Late recurrence",
author = "Takeshi Murata and Hiromitsu Jinno and Maiko Takahashi and Masayuki Shimoda and Tetsu Hayashida and Kaori Kameyama and Yuukou Kitagawa",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/tbj.13033",
language = "English",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence

AU - Murata, Takeshi

AU - Jinno, Hiromitsu

AU - Takahashi, Maiko

AU - Shimoda, Masayuki

AU - Hayashida, Tetsu

AU - Kameyama, Kaori

AU - Kitagawa, Yuukou

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence. Although several studies demonstrated that extended adjuvant endocrine therapy reduces the incidence of late recurrence, it remains unclear which hormone-receptor-positive patients have greater risks of late recurrence. Hormone-receptor-positive breast cancer patients were retrospectively selected from the prospective database of primary breast cancer patients treated at Keio University Hospital from January 1989 to December 2003. Late recurrence was defined as initial recurrence after 5 years from the initial surgery. We evaluated the clinicopathologic features of breast cancer patients with late recurrence. At a median follow-up of 10.9 years (range, 5.1-23.8), 371 patients had no recurrence, 90 had early recurrence (within 5 years), and 83 had late recurrence. Multivariate analysis revealed that >4 involved lymph nodes were significant risk factors for late recurrence (P < .001), whereas 1-3 positive nodes were not. Endocrine therapy significantly reduced the incidence of late recurrence (P < .001). After menopause, adjuvant therapy with aromatase inhibitors resulted in longer disease-free survival than tamoxifen (10-year disease-free survival: 97.6% vs 89.7%, P = .0955). High nodal involvement was significantly correlated with late recurrence in hormone-receptor-positive breast cancer patients. Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.

AB - The number of long-term breast cancer survivors with a risk of late recurrence is increasing. Hormone-receptor-positive patients have greater risks of late recurrence. Although several studies demonstrated that extended adjuvant endocrine therapy reduces the incidence of late recurrence, it remains unclear which hormone-receptor-positive patients have greater risks of late recurrence. Hormone-receptor-positive breast cancer patients were retrospectively selected from the prospective database of primary breast cancer patients treated at Keio University Hospital from January 1989 to December 2003. Late recurrence was defined as initial recurrence after 5 years from the initial surgery. We evaluated the clinicopathologic features of breast cancer patients with late recurrence. At a median follow-up of 10.9 years (range, 5.1-23.8), 371 patients had no recurrence, 90 had early recurrence (within 5 years), and 83 had late recurrence. Multivariate analysis revealed that >4 involved lymph nodes were significant risk factors for late recurrence (P < .001), whereas 1-3 positive nodes were not. Endocrine therapy significantly reduced the incidence of late recurrence (P < .001). After menopause, adjuvant therapy with aromatase inhibitors resulted in longer disease-free survival than tamoxifen (10-year disease-free survival: 97.6% vs 89.7%, P = .0955). High nodal involvement was significantly correlated with late recurrence in hormone-receptor-positive breast cancer patients. Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy.

KW - Extended endocrine therapy

KW - Hormone-receptor-positive breast cancer

KW - Late recurrence

UR - http://www.scopus.com/inward/record.url?scp=85045833711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045833711&partnerID=8YFLogxK

U2 - 10.1111/tbj.13033

DO - 10.1111/tbj.13033

M3 - Article

C2 - 29687661

AN - SCOPUS:85045833711

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

ER -